GHRP-2

GHRP-2 (also designated pralmorelin in some pharmaceutical research contexts) is a synthetic, second-generation growth hormone releasing peptide belonging to the GHRP class of secretagogues. It is a six-amino-acid peptide (His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) developed in the 1990s following earlier work on GHRP-6. Unlike growth hormone releasing hormone (GHRH) analogs such as CJC-1295, GHRPs act primarily on a distinct receptor — the ghrelin receptor (GHS-R1a) — making them mechanistically complementary rather than redundant when combined with GHRH-class compounds. As a research chemical, GHRP-2 is not approved for human use by the FDA, MHRA, EMA, or TGA. This content is for educational purposes only and does not constitute medical advice.

The primary mechanism of GHRP-2 involves agonism at the ghrelin receptor (GHS-R1a) in the hypothalamus and pituitary gland. This receptor activation triggers a robust, pulsatile release of endogenous growth hormone from somatotroph cells in the anterior pituitary. Research also suggests GHRP-2 weakly antagonizes somatostatin, the natural inhibitor of GH release, which may amplify the net GH pulse. Unlike exogenous recombinant human growth hormone (rhGH), GHRP-2 preserves the physiological pulsatility of GH secretion, a distinction researchers consider potentially relevant to downstream signaling differences. Secondary to GH release, IGF-1 elevation has been observed in studies, typically with a delay of several hours post-administration.

The evidence base for GHRP-2 includes a meaningful number of human trials by secretagogue standards, though most remain small and short-duration. Pralmorelin (the pharmaceutical-grade version of GHRP-2) was investigated in Japan as a diagnostic tool for GH deficiency assessment, where it received limited regulatory recognition. A number of peer-reviewed studies — including trials in healthy adults and GH-deficient populations — document significant acute GH elevation following intravenous or subcutaneous administration. Animal models (rodent and porcine) have explored effects on lean body mass accrual, wound healing, and cardiac protection, though these findings cannot be directly extrapolated to humans. User-reported outcomes in online communities describe improvements in sleep quality, recovery from training, and body composition shifts, but these reports are anecdotal, uncontrolled, and should be treated with appropriate skepticism.

Dosing ranges reported in published human research contexts have varied between approximately 1 mcg/kg and 2 mcg/kg per administration, typically administered subcutaneously or intravenously two to three times daily in research protocols. Some animal research has used higher weight-adjusted doses. These ranges are reported here strictly as a reflection of published research methodology — they do not constitute a dosing recommendation, and administration of this compound outside of a licensed research setting carries legal and health risks that have not been fully characterized. Researchers typically note that GHRP-2 is most commonly studied in combination with a GHRH analog to amplify GH pulse magnitude via complementary mechanisms.

GHRP-2 occupies an ambiguous legal space globally. In the United States it is unscheduled and unregulated as a research chemical but is not approved for human use. In the UK and EU it similarly falls under research-chemical frameworks without formal controlled-substance status, though human administration without a clinical trial authorization is legally and ethically problematic. In Australia, GHRP-2 is classified as a Schedule 4 (prescription-only) substance under the TGA's SUSMP, making unsupervised possession or use more restricted than in other regions. Vendors supplying GHRP-2 as a research chemical should provide third-party certificates of analysis (COA) verifying amino acid sequence, purity (HPLC ≥98%), residual solvent levels, and absence of microbial contamination. Lyophilized powder format should be stored frozen or refrigerated until reconstituted with bacteriostatic water, after which refrigeration and prompt use within standard research windows is indicated.